Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl.
Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
Type:
Application
Filed:
May 19, 2004
Publication date:
January 20, 2005
Applicant:
IRM LLC
Inventors:
Yuan Mi, Shifeng Pan, Nathanael Gray, Wenqi Gao, Yi Fan, Tao Jiang
Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
Type:
Application
Filed:
May 19, 2004
Publication date:
January 13, 2005
Applicant:
IRM LLC, a Delaware Limited Liability Company
Inventors:
Shifeng Pan, Nathanael Gray, Yuan Mi, Yi Fan, Wengi Gao
Abstract: The present invention is based on a novel cell tagging approach called “Differential Tag Length” method (DTLA) that allows the quantitative analysis of a mixture of multiple cell types (e.g., strains) grown in very small cultivation volumes. DTLA can also be fully automated and adapted for a high-throughput format. The invention provides methods for detecting proliferation of a mixture of cell types in a culture, for screening a library of compounds to identify those compounds that modulate proliferation of a cell, and for detecting the presence or absence of targets in a sample. The invention also provides kits comprising at least first polynucleotide tag and a second polynucleotide tag.
Type:
Application
Filed:
April 22, 2004
Publication date:
January 13, 2005
Applicant:
IRM LLC, a Delaware Limited Liability Company
Abstract: The invention provides novel modulatory polypeptides of TRAIL-induced apoptosis. The invention also provides methods for screening modulators of TRAIL-induced apoptosis. The methods comprise first screening test agents for modulators of a novel modulatory polypeptide of TRAIL-induced apoptosis and then further screening the identified modulating agents for modulators of TRAIL-induced apoptosis. The invention further provides methods and pharmaceutical compositions for modulating apoptosis of cells and for treating diseases and conditions such as cancers.
Type:
Application
Filed:
February 20, 2004
Publication date:
January 6, 2005
Applicant:
IRM LLC
Inventors:
Pedro Aza-Blanc, Michael Cooke, Quinn Deveraux, Christopher Cooper
Abstract: This invention provides novel methods and compositions for modulating T cell differentiation and T cell responses. The modulators are identified by screening test compounds for ability to modulate an inositol 1,4,5-trisphosphate 3-kinase (IP3K). The IP3K modulators can be further examined for their activity in modulating development of progenitor T cells (e.g., CD4+/CD8+ double positive T cells) into mature CD4+ or CD8+ single positive T cells. Pharmaceutical compositions comprising these T cell modulators can be administered to a subject to modulate T cell immune responses, to suppress inflammations, and to treat disease conditions such as autoimmune diseases, graft rejection or allergies.
Type:
Application
Filed:
January 23, 2004
Publication date:
December 30, 2004
Applicant:
IRM LLC, a Delaware Limited Liability Company
Inventors:
Michael P. Cooke, Karsten Sauer, Tim Wiltshire, Lisa Tarantino, Colin Fletcher, Ben Wen
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Type:
Application
Filed:
March 23, 2004
Publication date:
December 9, 2004
Applicant:
IRM LLC
Inventors:
Hong Liu, Phil Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li
Abstract: The present invention relates to bicyclic derivatives, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG/S1P receptor mediated signal transduction.
Type:
Application
Filed:
February 11, 2004
Publication date:
December 9, 2004
Applicant:
IRM LLC, a Delaware Limited Liability Company
Inventors:
Shifeng Pan, Nathanael S. Gray, Yuan Mi, Wenqi Gao, Yi Fan, Sophie Lefebvre
Abstract: The present invention provides highly automated fluid delivery systems and related methods with significantly improved throughput relative to preexisting technologies. In particular, the invention relates to a fluid dispensing system that simultaneously produces multiple fluid mixtures on-the-fly in multiple multiwell plates. The invention also includes control system and machine software in addition to various systems and related methods for performing assorted downstream processes.
Abstract: This invention provides novel methods for synthesis of narrow polydispersity oxazolone-containing polymers via nitroxide-mediated living free radical polymerization, as well as the products and derivatives thereof.
Abstract: The invention provides methods for inhibiting stem cell differentiation and for increasing the effective dose of stem cells in a subject. HSC differentiation can be inhibited by applying an HSC differentiation-inhibiting polypeptide identified in the present invention to an HSC culture in vitro, or administering the polypeptide to a subject in vivo. Some other methods of the invention comprise first obtaining a population of hematopoietic stem cells, introducing into the cells an HSC differentiation-inhibiting polynucleotide disclosed herein, and expressing the HSC differentiation-inhibiting polynucleotide in the cells. Such genetically modified stem cells can be administered to a subject whereby effective dose of the stem cells in the subject can be increased. This invention further provides novel molecular markers of hematopoietic stem cells, and methods for enriching hematopoietic stem cells using these novel markers.
Type:
Application
Filed:
February 11, 2004
Publication date:
December 2, 2004
Applicant:
IRM LLC, a Delaware Limited Liability Company
Abstract: The invention provides a novel class of cyclic compounds, pharmaceutical compositions comprising such cyclic compounds and methods of using such compounds to treat or prevent diseases and disorders associated with cyclin-dependent kinases (CDKs) activity, particularly diseases associated with the activity of CDK2 and CDK5.
Type:
Application
Filed:
March 5, 2004
Publication date:
November 25, 2004
Applicant:
IRM LLC
Inventors:
Pingda Ren, Francisco Adrian, Nathanael S. Gray, Xia Wang
Abstract: This invention provides a storage system and methods to accurately transfer of compounds between storage modules and work areas. The system for compound storage and retrieval provides a computer system operatively coupled to the storage modules to implement transfer operations. Methods can include redundant access and identification procedures to reduce errors in storage and retrieval of compounds.
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Type:
Application
Filed:
March 23, 2004
Publication date:
October 7, 2004
Applicant:
IRM LLC
Inventors:
Hong Liu, David Tully, Robert Epple, Badry Bursulaya, Jennifer Williams, Arnab Chatterjee, Jennifer Leslie Harris, Jun Li
Abstract: Methods and compositions for treating neurodegenerative diseases by modulating the interaction of ubiquitin to ubiquitin binding motifs are provided.
Abstract: This invention provides novel p53 modulatory polypeptides. The invention also provides methods for screening modulators of p53. The methods comprise first screening test agents for modulators of a p53-modulatory polypeptide and then further screening the identified modulating agents for modulators of p53. The invention further provides methods and pharmaceutical compositions for modulating p53 bioactivities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.
Type:
Application
Filed:
November 7, 2003
Publication date:
September 2, 2004
Applicants:
IRM LLC, The Scripps Research Institute
Inventors:
Qihong Huang, Sumit Chanda, John B. Hogenesch, Jeremy S. Caldwell
Abstract: The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage.
Type:
Application
Filed:
October 15, 2003
Publication date:
August 12, 2004
Applicants:
IRM LLC, The Scripps Research Institute
Abstract: A fermentation apparatus is constructed to produce a known and repeatable amount of untainted fermentation product using multiple fermentation vessels. To facilitate further processing compatible with other product processing steps, the fermentation apparatus has an array of sample vessels arranged in a container frame. The container frame is configured to hold the sample vessels during fermentation and to transport the vessel array to or from another processing station. Corresponding to the number of sample vessels in the sample vessel array, a cannula array is configured such that each cannula may be placed inside a sample vessel. The cannula array is attached to a gas distributor that delivers oxygen and/or one or more other gases from a gas source through the cannula into the sample vessel. Because the fermentation volume for each individual sample vessel is smaller than a bulk fermentation apparatus, the fermentation product yields are predictable and cell growth rates can be effectively optimized.
Type:
Application
Filed:
February 3, 2004
Publication date:
August 12, 2004
Applicant:
IRM, LLC
Inventors:
Robert Charles Downs, Scott Allan Lesley, James Kevin Mainquist, Daniel Terence McMullan, Andrew J. Meyer, Marc Nasoff
Abstract: The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.
Type:
Application
Filed:
October 21, 2003
Publication date:
August 12, 2004
Applicant:
IRM LLC, a Delaware LLC
Inventors:
Baogen Wu, Yun He, Truc Ngyuen, Kelli L. Kuhen, David Archer Ellis, Tao Jiang, Xiaohui Xe, Kunyong Yang, Badry Bursulaya